Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

June 4, 2026 8:40 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical...

Read more

Faron Pharmaceuticals Ltd: Holding(s) In Company

June 4, 2026 8:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON) (LSE:FARN) Company announcement:TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the issuer is a non-UK issuer (please mark...

Read more

Biolog Expands Service Lab Footprint and Eliminates Barriers Between Clients and Microbial Insights

June 4, 2026 5:00 AM

Biolog, Inc., a trusted leader in microbial identification and characterization, today announced the opening of a new Biolog Service Lab location on the West Coast, in Hayward, California. This expansion goes beyond increasing capacity; by co-locating the new lab with their R&D and instrument manufacturing teams, Biolog is creating a hub for innovation to continuously evolve their fast-growing microbial services.With Lab Service facilities now...

Read more

CEO Statement to Shareholders

June 3, 2026 12:05 PM

Dear Fellow Shareholders,As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:Strategic Focus and Business DevelopmentOver the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health....

Read more

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting

June 3, 2026 1:00 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland.At the AGM, the Board of Directors will propose the re-election of the current Board members and the election of Brad Hollinger, Founder, Chairman and Chief...

Read more

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

June 2, 2026 9:01 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe® System,...

Read more

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

June 2, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with...

Read more

Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape

June 2, 2026 2:30 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced that the company will host a webcast on Monday, June 8th, 2026, at 12:00 p.m. ET.The webcast will feature Dr. Phil Molyneaux, a leading expert in interstitial lung disease. In addition to his role as an investigator in the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis...

Read more

MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification

June 2, 2026 1:05 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced the sale of the U.S. and Canadian rights to RLF-OD032, a phenylketonuria program, as part of the Company's previously announced initiative to dispose of non-core assets and operations outside its core neurology focus. MindMaze Therapeutics will receive upfront cash consideration of USD 3...

Read more

Lobe Sciences Announces Proposed Shares for Debt Transaction

June 1, 2026 10:00 PM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in...

Read more

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

June 1, 2026 9:02 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in...

Read more

Edison Oncology Presents EO1001 Trials-in-Progress Poster at ASCO 2026, Highlighting Differentiated Activity in EGFR Extracellular Domain Mutant Cancers with No Approved Targeted Therapy

June 1, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company") today announced the presentation of a Trials-in-Progress poster detailing the ongoing Phase 1-2a study of EO1001, the Company's oral, brain-penetrant pan-ErbB inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 - June 2, 2026, in Chicago, Illinois."Patients whose tumors harbor EGFR extracellular domain mutations represent one of...

Read more

Synexis, LLC and Midwest Veterinary Supply Collaborate to offer DHP(R) Technology to Animal Health Professionals Nationwide

June 1, 2026 9:00 AM

Synexis and Midwest Veterinary Supply are collaborating to address the growing body of research highlighting the limitations of traditional cleaning protocols and the need for more advanced, continuous approaches to pathogen control in indoor animal health settings. With more than 65 years of experience supporting veterinary professionals, Midwest Veterinary Supply enables customers to adopt and scale next-generation solutions, including Synexis...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 1, 2026 8:18 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...

Read more

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

June 1, 2026 5:20 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it will host an in-person and virtual key opinion leader (KOL) event at GT30, Grev Turegatan 30 in Stockholm on Thursday, June 11, 2026 at 11:45 AM CEST. The event will feature Guilherme Perini MD, PhD (Hospital Israelita Albert Einstein), and Stefan K. Barta, MD, MS (Abramson Cancer Center,...

Read more

Faron Pharmaceuticals LTD: Holding(S) In Company

May 28, 2026 9:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer:Faron Pharmaceuticals Oy2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An acquisition or disposal of financial instruments☐ An event changing the breakdown of...

Read more

Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds

May 28, 2026 8:42 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board has resolved, based on the authorisation granted by the General Meeting held on 4 May 2026, to issue 8,000,000 additional Special Rights in connection with the First and Second Tranche of Bonds (originally announced on 3 April 2025 and 11 December 2025). 4,000,000 of the Special...

Read more

New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer

May 28, 2026 2:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer.The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica's FDA...

Read more

ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

May 27, 2026 4:30 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototype system. This device was built in partnership with the SONOCARELAB, at Sungkyunkwan...

Read more

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

May 27, 2026 9:06 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million.The acquisition follows OSRH's previously announced definitive global exclusive...

Read more